designtx.com (DSGN) - Cash on Hand per Share

Design Therapeutics aims for a monopoly in the treatment of genetic pathologies through GeneTACs. The change in cash per share on GURU.Markets reflects liquidity, where this metric equals 3.26. Design Therapeutics relies on external contractors for manufacturing, remaining a research center. However, the business's success depends on early test results and the control of the burn rate.
Comprehensive metric breakdowns and analytics for Design Therapeutics Inc (DSGN)

To objectively evaluate an issuer, it is essential for a manager to track the actual liquidity available to each shareholder, which allows for the prompt identification of capital dilution or write-downs. Analyzing the cash per share metric reveals the balance between financial stability and investment activity, which is critical for Design Therapeutics (DSGN) given the absence of revenue and the high development risks associated with the GeneTAC platform.